As of 2024-07-27, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -1.30. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 660.76 mil USD. SAGE's TTM EBITDA according to its financial statements is -507.44 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.4x - 17.5x | 13.7x |
| Forward P/E multiples | 20.9x - 24.8x | 23.7x |
| Fair Price | (137.44) - (115.09) | (122.86) |
| Upside | -1350.6% - -1147.3% | -1217.9% |
| Date | EV/EBITDA |
| 2024-07-26 | -1.30 |
| 2024-07-25 | -1.22 |
| 2024-07-24 | -1.21 |
| 2024-07-23 | -1.61 |
| 2024-07-22 | -1.57 |
| 2024-07-19 | -1.50 |
| 2024-07-18 | -1.48 |
| 2024-07-17 | -1.48 |
| 2024-07-16 | -1.48 |
| 2024-07-15 | -1.42 |
| 2024-07-12 | -1.42 |
| 2024-07-11 | -1.41 |
| 2024-07-10 | -1.31 |
| 2024-07-09 | -1.37 |
| 2024-07-08 | -1.29 |
| 2024-07-05 | -1.27 |
| 2024-07-03 | -1.25 |
| 2024-07-02 | -1.28 |
| 2024-07-01 | -1.31 |
| 2024-06-28 | -1.28 |
| 2024-06-27 | -1.26 |
| 2024-06-26 | -1.28 |
| 2024-06-25 | -1.29 |
| 2024-06-24 | -1.39 |
| 2024-06-21 | -1.32 |
| 2024-06-20 | -1.25 |
| 2024-06-18 | -1.27 |
| 2024-06-17 | -1.34 |
| 2024-06-14 | -1.45 |
| 2024-06-13 | -1.38 |
| 2024-06-12 | -1.28 |
| 2024-06-11 | -1.24 |
| 2024-06-10 | -1.29 |
| 2024-06-07 | -1.24 |
| 2024-06-06 | -1.27 |
| 2024-06-05 | -1.30 |
| 2024-06-04 | -1.26 |
| 2024-06-03 | -1.32 |
| 2024-05-31 | -1.32 |
| 2024-05-30 | -1.38 |
| 2024-05-29 | -1.28 |
| 2024-05-28 | -1.44 |
| 2024-05-24 | -1.42 |
| 2024-05-23 | -1.35 |
| 2024-05-22 | -1.47 |
| 2024-05-21 | -1.46 |
| 2024-05-20 | -1.33 |
| 2024-05-17 | -1.41 |
| 2024-05-16 | -1.45 |
| 2024-05-15 | -1.41 |